Despite its small base, rapid growth in smart insulin administration, connected devices, patient-centric care, and home-based ...

According to DataM Intelligence, the Insulin Delivery Devices Market Size reached USD 20.26 billion in 2024 and is projected to reach USD 43.11 billion by 2033, growing at a strong CAGR of 8.8% from ...

A material that slips through skin might someday make needle-free insulin possible for people with diabetes. In mice and mini pigs, attaching the permeating polymer to insulin and applying the ...

Corp., a large manufacturer of insulin injection devices, has expanded its partnership with Direct Relief, a leading humanitarian aid organization and large charitable insulin provider in the ...

The Go-Pen insulin pen. [Image courtesy of the company] Go-Pen announced today on social media that it received CE mark approval for its user-fillable insulin pen. The Denmark-based company said on ...

The use of automated insulin delivery systems (AID) is standard of care for people with type 1 diabetes. However, the limited capacity of insulin pump cartridges, which can hold 1.6-3.0mL or the ...

Share on Pinterest Experts say California’s new affordable insulin program is a breakthrough for people with diabetes. Getty Images California has launched a program to manufacture and sell lower-cost ...

The new CalRx insulin will work as a generic version of glargine and could save patients $2000 to $4000 per year. HealthDay News — California will start selling low-cost insulin Jan. 1, nearly three ...

Litigation over Medtronic Plc’s alleged scheme to avoid $100 million in deal payments by sabotaging sales of a reusable insulin pen ended with an anticlimax Monday. The order formally dismissing the ...

California Gov. Gavin Newsom announces CalRx-branded insulin glargine pens available beginning Jan. 1, 2026, at a suggested retail price of no more than $55 per five-pack, or $11 per pen, during a ...

(AP) — Gov. Gavin Newsom said Thursday that California will begin selling affordable insulin under its own label on Jan. 1, nearly three years after he first announced a partnership to sell ...

The state of California is teaming up with the nonprofit generic drug maker Civica Rx and Biocon Biologics to offer an interchangeable biosimilar insulin glargine pen for $11 beginning January 1, 2026 ...